New Study Links Neuropilin 2 Deficiency to Inflammation-Induced Edema and Lymphedema – Clues to New Pathways for Treatment

Unexpected massive, persistent fluid accumulation and fewer lymphatic capillaries lead to formulation of new hypothesis, according to a new report in The American Journal of Pathology

Philadelphia, PA, October 14, 2016

Fluid accumulation and swelling (edema) may result from the malfunctioning of regulatory processes controlling vessel permeability in the body. Edema frequently occurs in chronic inflammatory diseases including psoriasis and eczema. Capillaries in the lymphatic system usually drain the excess fluid but their dysfunction can lead to another serious condition: lymphedema. A new study published in The American Journal of Pathology found that deficiency in neuropilin 2 (Nrp2) receptors in vascular endothelial cells results in excessive and prolonged fluid build-up after inflammation. This discovery may guide investigators toward new pharmacological therapies for edema and lymphedema.

The newest research for lead investigator Diane R. Bielenberg, PhD, began with a twist. Bielenberg, an Assistant Professor in the Department of Surgery, Harvard Medical School and Vascular Biology Program, Boston Children’s Hospital (Boston), described how previous studies that inhibited vascular endothelial growth factor receptors (VEGFRs, the co-receptors of Nrp2) have shown reduced blood vessel permeability following inflammation. “Therefore, we expected to see less permeability after inflammation in neuropilin 2 (Nrp2) knockout mice,” Bielenberg explained. To her team’s surprise, the Nrp2 knockout mice showed massively increased and prolonged edema following inflammation. Investigation into this finding led Bielenberg’s laboratory to formulate a novel hypothesis – that endogenous Semaphorin 3F (Sema3F) protein acting through Nrp2 inhibits vascular permeability and edema. Additional experiments and data support this new hypothesis.

The investigators measured ear swelling in mice after topically introducing an inflammation-causing substance. Fluid retention was 2.5-fold higher in the Nrp2-deficient mice than controls. The swelling in control mice began to recede within two days of inflammation and returned to near-normal levels by four days. In contrast, the swelling in the Nrp2-deficient mice remained significantly elevated over control levels for more than 10 days.

Lymphangiography in a mouse ear after induction of inflammation. This photograph highlights the structure of both the vascular and lymphatic systems. The ear is injected intradermally with blue dye to visualize the lymphatic vessels (lymphangiography). The blood vessels are visible through the skin and appear red. The blood vessels display a branching pattern; the lymphatic capillary plexus has many looping, interconnected circular structures to promote drainage in the instance of an isolated blockage. In a normal mouse, lymphatic fluid flows in one direction: from the tip of the ear to the base of the ear or from the capillary to the lymph node. The image was taken after the induction of inflammation and shows retrograde flow, pooling, and leakage of the blue lymphatic fluid, conditions that exemplify lymphedema. Photo credit: Kristin Johnson

The researchers also found that in Nrp2-mutant mice the lack of a superficial lymphatic capillary plexus causes impaired drainage of fluid. Co-investigators Patrick Mucka, MS, and Nicholas Levonyak, MS, of the Vascular Biology Program at Boston Children’s Hospital, explain that the prolonged lymphedema seen in Nrp2 knockout mice may be caused by architectural defects resulting from improper lymphatic vessel sprouting during development.

Interestingly, the enhanced leakage in the Nrp2-deficient mice was associated with the loss of endogenous Sema3F activity. Sema3F competes with VEGFA for binding to Nrp2 and is therefore termed an inhibitory ligand of Nrp2. This competitive inhibition, in turn, prevents vascular permeability. Addition of exogenous Sema3F protein therefore inhibits edema. Dr. Bielenberg encourages the pursuit of future studies on the role of the Sema3F/Nrp2 axis in chronic inflammation or lymphedema. Although these studies were performed in mice, mutations in the human NRP2 gene have been found in patients with primary lymphedema. This gene conservation suggests a high likelihood that humans and mice share a similar molecular mechanism behind this process, an encouraging indication for the translation of these findings.


Notes for editors
The article is "Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency," by by Patrick Mucka, Nicholas Levonyak, Elena Geretti, Bernadette M.M. Zwaans, Xiaoran Li, Irit Adini, Michael Klagsbrun, Rosalyn M. Adam, and Diane R. Bielenberg (doi:10.1016/j.ajpath.2016.07.022). It appears in The American Journal of Pathology, volume 186, issue 11 (November 2016), published by Elsevier.

Full text of this study is available to credentialed journalists upon request; contact Eileen Leahy at +1 732-238-3628 or Journalists wishing to interview the authors should contact Diane R. Bielenberg, Ph.D. at

This research was supported by the Vascular Biology Program at Boston Children’s Hospital and the NIH under award numbers CA118732, CA155728 (DRB), CA037392 (MK), and DK65298 (RMA).

About The American Journal of Pathology
The American Journal of Pathology, the official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.

The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, The American Journal of Pathology is the most highly cited journal in Pathology – close to 40,000 cites in 2015 – with an Impact Factor of 4.206 and Eigenfactor of 0.05638 according to the 2015 Journal Citation Reports®, Thomson Reuters, 2016, and an h-index of 228 according to the 2015 SCImago Journal and Country Rank.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contact
Eileen Leahy
+1 732-238-3628

Dr. Chhavi Chauhan
Scientific Editor
The American Journal of Pathology
+1 301-634-7953